Introduction
After introduction into humans, a swine-origin influenza A H1N1 virus (S-OIV) has rapidly caused global transmission in a couple of months and led to the declaration of the 2009 pandemic by World Health Organization on June 11, 2009. Although the overall clinical symptoms of the disease are mild and similar to those caused by seasonal influenza, there have been severe cases and it has claimed over 5700 human lives worldwide by the end of October, 2009 (http://www.who.int/csr/don/2009_10_30/en/index.html). Genetic analysis showed the pandemic (H1N1) 2009 virus has undergone very limited genetic mutations up to now (http://www.who.int/csr/ don/2009_10_16/en/index.html). The virulence markers which were frequently observed in avian H5N1 virus infection of mammals were absent . However, there is still a concern that the pandemic (H1N1) 2009 virus may evolve into a more virulent form as that observed in the "Spanish flu" during the fall of 1918.
Pathogenicity of influenza virus involves polygenic traits. Residue 627 of the polymerase basic protein 2 (PB2) was recognized as one of the most important determinants (Subbarao et al., 1993; Hatta et al., 2001 ). The E627K substitution was observed to enhance virulence and viral replication in mice and other mammals (Mase et al., 2006; Manzoor et al., 2009; Steel et al., 2009; Le et al., 2009) . It was also reported to contribute to the improved replication of H5N1 influenza virus at the lower temperature of 33°C, thus conferring to the virus advantages for efficient growth in the upper respiratory tracts of mammals and transmission (Massin et al., 2001; Hatta et al., 2007; Steel et al., 2009; Van Hoeven et al., 2009) . Notably, all previous human influenza viruses established through the three pandemics in the 20th century contained 627K in PB2, while most of avian influenza viruses carried glutamic acid (E) instead. Genetic analysis showed that swine influenza viruses had either K or E at this position and current human pandemic (H1N1) 2009 viruses possessed a 627E (Influenza Virus Resource, NCBI, www.ncbi.nlm.nih.gov/genomes/FLU/). Whether the substitution of E627K in PB2 gene of the pandemic (H1N1) 2009 virus may occur after prevailing in humans for a period of time, and whether such change may alter the virulence of the current pandemic H1N1 virus is still unknown.
To investigate the potential pathogenic effect of PB2 E627K substitution in the pandemic (H1N1) 2009 virus, we reconstructed a recombinant virus with a single residue substitution at PB2 627 position from the A/California/04/2009 strain and tested its pathogenicity in mice and its growth properties in MDCK cells under different temperatures. Our findings suggested that a 627K substitution in PB2 gene does not confer higher virulence or growth properties for the pandemic (H1N1) 2009 virus.
Results

Effects of PB2 E627K substitution on the viral replication and pathogenicity of A/California/04/2009 (H1N1) virus in mice
To assess the potential effect of a PB2 E627K substitution on the pandemic (H1N1) 2009 virus, we constructed a recombinant virus by introducing a lysine into the 627 position of PB2 gene in the background of A/California/04/2009 (CA04). The pathogenicity and viral growth properties in the lung tissues were compared between the reconstituted wild-type CA04 627E and its 627K counterpart in infected mice. Groups of 22 mice were inoculated with 10 3 or 10 5 PFU of viruses respectively.
The clinical signs and body weight change from the infected mice were monitored daily for 14 days. Our results showed that inoculation of CA04-RG-627E or CA04-RG-627K viruses with either 10 3 or 10 5 PFU was not lethal to mice. Mice infected with a 10 5 PFU dose of either virus experienced body weight loss starting on 2 d.p.i., and reached the lowest level on 6 d.p.i. However, there was no significant difference between the CA04-RG-627E and the CA04-RG-627K groups (P N 0.05) (Fig. 1) .
Overt clinical signs were observed on 3-4 d.p.i., when most infected mice in these groups suffered from inactivity, anorexia and ruffled fur. Animals infected with a lower dose of either viruses (10 3 PFU) showed milder symptoms and less weight loss (P b 0.001), compared with those from the higher dose inoculation groups (Fig. 1 ). Mice infected with 10 3 PFU of CA04-RG-627K virus had slightly less weight loss than those infected with the same dose of CA04-RG-627E virus throughout the course of the experiment (P b 0.001) (Fig. 1) . CA04 virus was reported to cause prominent bronchitis, alveolitis and efficient viral replication in the lung tissues of infected mice (Itoh et al., 2009) . In this study, we examined virus replication in trachea, lungs, intestines and brain tissues of the infected mice. No virus replication was observed beyond the pulmonary system of mice infected with either CA04-RG-627E or CA04-RG-627K virus by histochemical staining of viral nucleoprotein (data not shown). Notably, viral replication was observed in mice lungs from the first day post-infection ( Fig. 2) , implicating the tendency of replication in the lower respiratory tract by the pandemic (H1N1) 2009 virus. Consistent with the observation of body weight changes, virus growth in lung tissue was observed during the first 4 days post-infection ( Fig. 2) , and a lower dose of virus inoculation resulted in less severe lung lesions, with viral antigen (nucleoprotein, NP) mostly detected in the terminal bronchiolar epithelia and desquamated cells in the bronchiolar lumen (Fig. 3) . Examination of virus replication activity with quantitative RT-PCR found that virus replication reached the highest level on the first 2 days post-infection, decreased gradually thereafter; and virus was cleared after 7 days post-infection (Fig. 2b) . Although 627K of PB2 gene was reported to associate with increased virus replication, our results found no significant difference in virulence and virus replication in lung tissues of infected mice with the PB2 627K and 627E viruses derived from the pandemic (H1N1) 2009 virus (P N 0.05) (Figs. 2 and 3). It is important to note that while mice infected with 10 5 PFU of viruses exhibited more body weight loss ( Fig. 1 ), examination of virus titer in lung tissues found that there was a significant reduction in virus titer from a 10 5 PFU dose of both 627E
and 627K groups on day 7 post-infection (Fig. 2a) . It remains to be investigated if inoculation with a higher dose of virus may induce a stronger host immune response, leading to the rapid clearness of virus in the lung.
Effects of PB2 E627K substitution on the growth property of CA04 on MDCK cells at different temperatures
The E627K substitution in PB2 gene of avian H5N1 influenza virus was reported to be responsible for the increased growth efficiency in mammals, especially at lower temperatures of 32-33°C (Massin et al. 2001; Hatta et al., 2007) . Our animal experiment showed CA04-RG-627K did not change growth properties of the pandemic (H1N1) 2009 virus in mouse lung tissues, with the body temperature at approx. 37-39°C. We then further characterized the growth kinetics of CA04-RG-627E and CA04-RG-627K viruses at different temperatures in MDCK cells. Both viruses were shown to be sensitive to temperature change and had severe growth delay at 33°C (P b 0.01) during the first 48 h.p.i (Fig. 4) . No significant difference was observed between these two viruses in replication kinetics at all temperatures tested (33-39°C) Fig. S1 ).
Discussion
Increasing evidence strongly suggested that the amino acid at 627 position of the polymerase basic protein 2 (PB2) is associated with host range adaptation (Subbarao et al., 1993; Gabriel et al., 2007; Labadie et al., 2007) . Of note, most avian and all equine influenza viruses have a glutamic acid (E), so does the pandemic (H1N1) Studies on viral pathogenicity revealed that a single amino acid substitution of E627K in PB2 would remarkably enhance the virulence of avian H5N1 and equine H7N7 influenza viruses in mammalian species (Hatta et al., 2001; Shinya et al., 2007; Munster et al., 2007) . Most strikingly, a single passage in mice was reported to be sufficient for the avian H5N1 virus to acquire the E627K substitution, and all recovered viruses from the brains of dead mice turned out to have a 627K (Mase et al., 2006) . In addition to H5 and H7 subtypes, PB2 627K was also found to confer increased transmission and plaque-forming abilities for human H3N2 and pandemic 1918 strain (Van Hoeven et al., 2009; Steel et al., 2009 ). As such, a lysine at PB2 627 position has been considered as one of the most important determinants of pathogenicity and host range for influenza viruses. Whether current pandemic H1N1 virus may evolve to obtain E627K substitution remains to be seen. However, it would be important to examine if the 627K variant may result in altered virulence in animal models, which would have a significant implication on this undergoing pandemic.
In this study, we demonstrated that the single amino acid substitution of PB2 E627K, in the context of the current influenza pandemic stain, rendered neither increased pathogenicity in mice, nor improved viral replication in MDCK cells under 33-39°C. As the normal temperatures of human distal and proximal airways are approximately within this range, a reasonable predictive implication can be deduced that a lysine at PB2 627 position might not confer improved viral replication and virulence in humans.
The difference on effects of the PB2 627K residue in pandemic (H1N1) 2009 from this study and previous reports mainly in H5N1 and H7N7 subtypes may be due to the different interactions between PB2 and other viral genes in the different genetic context of these viruses. It was reported that increased virulence in mice caused by the E627K mutation in H5N1 avian influenza virus could be compensated by multiple mutations at other sites of PB2 gene (L89V, G309D, T339K, R477G, I495V and A676T), suggesting that E627K substitution may not be an indispensable determinant for virulence ). Genetic analysis revealed that the pandemic (H1N1) 2009 contained all six "compensating" residues in PB2 gene. In another study, substitutions at 590 and 591 positions in PB2 gene was reported to act as adaptive strategies for the pandemic (H1N1) 2009 virus polymerase to replicate in humans (Mehle and Doudna, 2009 ). These evidences may partially explain why the pandemic (H1N1) 2009 virus can replicate and transmit efficiently in humans without the function of PB2 627K.
With the pandemic (H1N1) 2009 virus continues to circulate in humans, it is likely that more adaptive mutations will emerge along the course of transmission in humans. Acquisition of possible pathogenic determinants through mutation or gene reassortment with other influenza viruses may generate more virulent variants. Our study, however, suggested that the 627K mutation in PB2 alone, if it occurs, may not raise the risk significantly.
Materials and methods
Viruses and cells
The reference human H1N1 virus, A/California/04/2009 (CA04), was kindly provided by the World Health Organization Collaborating Centers for Reference and Research on Influenza (Atlanta, GA, USA). Madin-Darby canine kidney (MDCK) and human embryonic kidney (HEK) 293T cells were obtained from the American Type Culture Collection (ATCC) and propagated in Eagle's minimal essential medium (MEM) and Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS), respectively. Viral stocks were prepared in MDCK cells. All experiments with live viruses and transfectants were conducted in biosafety level 3 (BSL3) containment laboratories.
Generation of recombinant viruses by reverse genetics
The CA04-derived recombinant viruses were generated as previously reported (Hoffmann et al., 2001) . In brief, viral RNA was extracted from CA04 stocks using QIAamp viral RNA minikit (QIAGEN). The cDNAs was synthesized with Uni12 primer using Transcriptor High Fidelity cDNA synthesis Kit (Roche). All eight viral genes of CA04 were amplified using PfuUltra® II Fusion HS DNA Polymerase (Stratagene) and cloned into pHW2000 plasmid. QuikChange® II Site-Directed Mutagenesis Kit (Stratagene) was used for generation of E627K mutations in PB2 gene. All plasmids were sequenced to ensure the absence of unwanted mutations.
The rescue of infectious virus from cloned cDNA was conducted as previously described (Hoffmann et al., 2000) . Briefly, 293T cells were co-cultured with MDCK cells in opti-modified Eagle's medium (Opti-MEM) (Gibco/Life technologies) supplemented with 1.5% (v/v) of Antibiotic Antimycotic Solution (100×) (Sigma). After overnight incubation, sub-confluent (70%) monolayers were used for co-transfection with eight plasmids (1 μg each plasmid) using TransIT®-LT1 Transfection Reagent (Mirus). 48-72 h after transfection, culture supernatant was inoculated to MDCK cells and then passaged for preparation of viral stocks. Identities of the recombinant viruses were confirmed by sequencing before the animal test. The reverse geneticsderived virus with all wild-type gene segments of CA04 was designated as CA04-RG-E while that with a single E627K substitution in PB2 gene as CA04-RG-K.
Virus growth kinetics in MDCK cell culture
MDCK cells were infected with each virus in triplicate at a multiplicity of infection (MOI) of 0.001 and incubated at 33, 35, 37 or 39°C. Aliquots of the supernatants were collected at 6, 12, 24, 36, 48, 60, 72 and 78 h post-inoculation (h.p.i.) and titrated by real-time RT-PCR and plaque assay on MDCK cells.
Pathogenicity test in mice
Eight-to nine-week-old female BALB/c mice were used in this study. Baseline body weights were established prior to infection. Twenty-two mice per group were intranasally inoculated with 10 3 or 10 5 PFU (plaque-forming unit) of viruses in 25 μl of PBS under light anaesthesia by inhalation of 4% isoflurane. For the mock group, 25 μl of PBS was used. Body weight, clinical signs of infection, and survival were monitored daily for 14 days and mice with body weight loss greater than 25% of pre-infection values were euthanized humanely. Three mice from each group were sacrificed respectively on days 1, 2, 3, 4, 7 post-infection (d.p.i.). The remainders (7 mice per group) were kept for observation and euthanatized at the end of the experiment (14 d.p.i.).
Viral titration from the mouse organs
Tissues for viral titrations were removed and kept at − 80°C until homogenized in a 9 fold volume of cold PBS and clarified by centrifugation. Virus titers of homogenates were determined by plaque assays in MDCK cells and by real-time PCR.
Pathological examination
Freshly excised tissues of the trachea, lungs, intestines and brains from the mice were preserved in 10% phosphate-buffered formalin. After 24 h' fixation, tissues were dehydrated, embedded in paraffin, and cut into 5-μm-thick sections. For sections from each tissue sample, a standard histochemistry staining procedure with hematoxylin and eosin (Sigma) (H&E) as well as immunohistochemistry (IHC) assay with a mouse anti-NP monoclonal antibody (provided by the National Institute of Diagnostics and Vaccine Development for Infectious Diseases, Xiamen University) was performed in parallel. Goat anti-mouse IgG-biotin conjugate secondary antibody was purchased from Calbiochem. Specific viral antigen was visualized by 3,3′-diaminobenzidaine tetrahydrochloride staining as brown. Nine discrete, non-overlapping fields of view with a magnification of 400× were observed for each section and the number of positive viral antigen was calculated.
Real-time RT-PCR
Viral RNA was extracted from CA04 stocks using QIAamp viral RNA minikit (QIAGEN) and cDNAs were synthesized with Uni12 or random primers using Transcriptor High Fidelity cDNA synthesis Kit (Roche). Copy numbers of the influenza M segment were determined on a LightCycler® 480 Real-Time PCR System (Roche) with LightCycler® FastStart DNA Master PLUS SYBR Green I Kit (Roche) and normalized by the expression of β-Actin gene. Primers used for the analysis of M gene were M-146F (GACCRATCCTGTCACCTCTGAC) and M-251R (AGGGCATTYTGGACAAAKCGTCTA), while those for β-Actin gene were Act-1132F (TGGATCAGCAAGCAGGAGTATG) and Act-1188R (GCATTTGCGGTGGACGAT).
Statistical analysis
Statistical analysis was performed by Mean Analysis with PASW Statistics 18 (SPSS Inc., Chicago IL). The probability of a significant difference was computed using ANOVA (analysis of variance). Results were considered significant at P b 0.05.
